Table 1_Prognostic impact of the combined effects of lipoprotein(a) and homocysteine in pa

1,741 patients with premature myocardial infarction (aged ≤55 years) were prospectively enrolled at Tianjin Chest Hospital from January 2018 to June 2023. The dataset likely contains clinical and laboratory measurements, including lipoprotein(a) and homocysteine levels, used to assess major adverse cardiovascular event (MACE) risk over a median follow-up of 19.6 months. The study was authored by Yuhang Wang and shared under a CC-BY-4.0 license.

Use Cases

• Train prognostic models for major adverse cardiovascular events based on lipoprotein(a) and homocysteine levels.
• Analyze the additive interaction between lipid and thrombotic biomarkers for risk stratification.
• Validate a dual-threshold risk assessment strategy (50 mg/dL Lp(a) and 15 μmol/L HCY) in a clinical cohort.

Strengths

• Prospective cohort design with 1,741 enrolled patients provides a defined study population.
• Median follow-up of 19.6 months allows for longitudinal outcome assessment.
• Analysis includes advanced statistical methods like restricted cubic splines and net reclassification improvement.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count for the underlying data is unknown, which may limit suitability assessment.
• Data may reflect geographic bias inherent to a single hospital center in Tianjin.

Provenance

Source

Tianjin Chest Hospital

Collection Method

Prospective cohort study

Time Range

January 2018 to June 2023 (enrollment), with a median follow-up of 19.6 months.

Freshness

Last updated 2026-06-02 04:21:02; freshness should be verified.

Geography

Tianjin, China